Breaking News

Showa Denko Materials, Kidswell Bio Enter Cell Therapy Alliance

Minaris will provide process development services and potential clinical manufacturing of cell therapy products by the end of 2024.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Showa Denko Materials Co., Ltd. and Kidswell Bio Corp. have entered an agreement to enable process development and clinical manufacturing of cell therapy products using the advantage of SHED*2 (Stem cells from Human Exfoliated Deciduous teeth) which is under development by Kidswell Bio. Under the agreement, Minaris Regenerative Medicine Co., Ltd., a subsidiary of Showa Denko Materials, will provide process development services and potential clinical manufacturing of cell therapy products by the ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters